Hydrochloric Acid

Hydrochloric Acid

SCHEMBL4469227

CCC1=C([Zr+2](c2cccc3c2Cc2ccccc2-3)=[Si](C)C)CC=C1.[Cl-].[Cl-]

nearest known ligand 0.36

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA

The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
PNMT P11086 1/20 0.35
DRD2 P14416 1/20 0.32
DRD4 P21917 1/20 0.32
DRD3 P35462 1/20 0.32
NPC1 O15118 1/20 0.32
RAB9A P51151 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL3115118 0.85 PNMT (0.34) PNMTNPC1RAB9A
Hydrochloric Acid SCHEMBL30661101 0.80 PNMT (0.44) PNMTDRD2DRD4DRD3NPC1
Hydrochloric Acid SCHEMBL3119416 0.80 PNMT (0.44) PNMTDRD2DRD4DRD3NPC1
Hydrochloric Acid SCHEMBL6915300 0.77 PNMT (0.35) PNMTNPC1RAB9A
Hydrochloric Acid SCHEMBL4475731 0.77 PNMT (0.33) PNMTDRD2DRD4DRD3NPC1
Hydrochloric Acid SCHEMBL2858645 0.75 PNMT (0.35) PNMTDRD2DRD4DRD3NPC1
Hydrochloric Acid SCHEMBL7772202 0.73 PNMT (0.44) PNMTDRD2DRD4DRD3NPC1
Hydrochloric Acid SCHEMBL5079477 0.70 PNMT (0.35) PNMTDRD2DRD4DRD3NPC1
Hydrochloric Acid SCHEMBL4465753 0.70 PNMT (0.35) PNMTDRD2DRD4DRD3NPC1
Hydrochloric Acid SCHEMBL5081164 0.70 PNMT (0.36) PNMTDRD2DRD4DRD3NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1880986-B1 PROCESS FOR PRODUCING SATURATED ALIPHATIC HYDROCARBONS, AND LUBRICANT COMPOSITIONS THEREOF IDEMITSU KOSAN CO (JP) 2013-03-06 EP disclosed
US-8373011-B2 Used in a base oil of lubricant having good low temperature fluidity, low evaporativity, and thermal stability and oxidation stability IDEMITSU KOSAN CO., LTD. (JP) 2013-02-12 US disclosed
EP-0945471-B1 CATALYSTS FOR THE POLYMERIZATION OF OLEFINS, PROCESS FOR THE PRODUCTION OF OLEFIN POLYMERS, AND PROCESSES FOR THE PRODUCTION OF STYRENE POLYMERS IDEMITSU KOSAN CO (JP) 2009-05-13 EP disclosed
US-20080146469-A1 Process for producing saturated aliphatic hydrocarbon compound, and lubricant composition IDEMITSU KOSAN CO., LTD. (JP) 2008-06-19 US disclosed
EP-1880986-A1 PROCESS FOR PRODUCING SATURATED ALIPHATIC HYDROCARBON COMPOUND, AND LUBRICANT COMPOSITION IDEMITSU KOSAN CO., LTD. (JP) 2008-01-23 EP disclosed
US-6787499-B2 Catalyst for the production of α-olefin and α-olefin production method IDEMITSU PETROCHEMICAL CO., LTD. (JP) 2004-09-07 US disclosed
US-20040097366-A1 Polyolefin-based composite resin, method for production thereof, catalyst for polymerization of vinly compound and method for polymerization of vinly compound using the same IDEMITSU KOSAN CO. LTD. (JP) 2004-05-20 US disclosed
US-20030134991-A1 Catalyst for the production of alpha-olefin and alpha-olefin production method thereof IDEMITSU PETROCHEMICAL CO., LTD. (JP) 2003-07-17 US disclosed
US-6555633-B1 A alpha-olefin oligomerization catalyst obtained by contacting (a) a clay, clay mineral or ion-exchange layer compound with (b-1) a transition metal complex of group 4 to 6 of periodic table, and (a) is treated with organosilane compound IDEMITSU PETROCHEMICAL CO., LTD. (JP) 2003-04-29 US disclosed
US-6524985-B1 Organoboroaluminum reaction product of an alkylboronic acid and an alkylaluminum halide, alkylaluminum hydride or alkylaluminum siloxide MITSUBISHI CHEMICAL CORPORATION (JP) 2003-02-25 US disclosed
EP-0589638-A2 Powder catalyst composition and process for polymerizing olefins with the use thereof MITSUBISHI CHEMICAL CORPORATION (JP) 1994-03-30 EP disclosed
EP-0574258-A2 Process for producing alpha-olefin polymers MITSUBISHI CHEMICAL CORPORATION (JP) 1993-12-15 EP disclosed
EP-0570126-A1 Method for producing graft-modified copolymers MITSUBISHI CHEMICAL CORPORATION (JP) 1993-11-18 EP disclosed
EP-0566349-A2 Process for producing alpha-olefin polymers MITSUBISHI CHEMICAL CORPORATION (JP) 1993-10-20 EP disclosed
US-5252677-A Epoxy, hydroxy or sulfonic acid end groups MITSUBISHI PETROCHEMICAL COMPANY LIMITED (JP) 1993-10-12 US disclosed
US-5225501-A Transition metal compound and alumoxane catalyst MITSUBISHI PETROCHEMICAL COMPANY LIMITED (JP) 1993-07-06 US disclosed
EP-0512741-A1 Process for producing a propylene random copolymer MITSUBISHI CHEMICAL CORPORATION (JP) 1992-11-11 EP disclosed
EP-0511846-A1 Aminated olefin polymers MITSUBISHI CHEMICAL CORPORATION (JP) 1992-11-04 EP disclosed
EP-0498675-A2 Production of alpha-olefin polymers MITSUBISHI CHEMICAL CORPORATION (JP) 1992-08-12 EP disclosed
EP-0487278-A2 Functionalized olefin polymers MITSUBISHI CHEMICAL CORPORATION (JP) 1992-05-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080146469-A1 Process for producing saturated aliphatic hydrocarbon compound, and lubricant composition ALOX15, ALOX12, ALOX15B PNMT 3641/4885DRD2 318/4885DRD4 527/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.